Your browser doesn't support javascript.
loading
FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs.
O'Shaughnessy, Elizabeth; Yasinskaya, Yuliya; Dixon, Cheryl; Higgins, Karen; Moore, Jason; Reynolds, Kellie; Ampel, Neil M; Angulo, David; Blair, Janis E; Catanzaro, Antonino; Galgiani, John N; Garvey, Edward; Johnson, Royce; Larwood, David J; Lewis, Gareth; Purdie, Rob; Rex, John H; Shubitz, Lisa F; Stevens, David A; Page, Stephen J; Shukla, Sunita J; Farley, John J; Nambiar, Sumathi.
Afiliação
  • O'Shaughnessy E; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
  • Yasinskaya Y; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
  • Dixon C; Division of Biometrics IV, Office of Translational Sciences, CDER, FDA, Silver Spring, Maryland, USA.
  • Higgins K; Division of Biometrics IV, Office of Translational Sciences, CDER, FDA, Silver Spring, Maryland, USA.
  • Moore J; Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, CDER, FDA, Silver Spring, Maryland, USA.
  • Reynolds K; Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, CDER, FDA, Silver Spring, Maryland, USA.
  • Ampel NM; Valley Fever Center for Excellence, University of Arizona, Tucson, Arizona, USA.
  • Angulo D; SCYNEXIS, Inc., Jersey City, New Jersey, USA.
  • Blair JE; Mayo Clinic, Phoenix, Arizona, USA.
  • Catanzaro A; University of California, San Diego, La Jolla, California, USA.
  • Galgiani JN; Valley Fever Center for Excellence, University of Arizona, Tucson, Arizona, USA.
  • Garvey E; Mycovia Pharmaceuticals, Inc., Durham, North Carolina, USA.
  • Johnson R; Valley Fever Institute, Kern Medical, Bakersfield, California, USA.
  • Larwood DJ; Valley Fever Solutions, Inc., Tucson, Arizona, USA.
  • Lewis G; Mayne Pharma, Raleigh, NC, USA.
  • Purdie R; Valley Fever Institute, Kern Medical, Bakersfield, California, USA.
  • Rex JH; F2G, Ltd., Manchester, United Kingdom.
  • Shubitz LF; Valley Fever Center for Excellence, University of Arizona, Tucson, Arizona, USA.
  • Stevens DA; California Institute for Medical Research, San Jose, California, and Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
  • Page SJ; DRT Strategies, Inc., Arlington, Virginia, USAand.
  • Shukla SJ; Office of Infectious Diseases, Office of New Drugs, CDER, FDA, Silver Spring, Maryland, USA.
  • Farley JJ; Office of Infectious Diseases, Office of New Drugs, CDER, FDA, Silver Spring, Maryland, USA.
  • Nambiar S; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Clin Infect Dis ; 74(11): 2061-2066, 2022 06 10.
Article em En | MEDLINE | ID: mdl-34651656

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coccidioidomicose Tipo de estudo: Prevalence_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coccidioidomicose Tipo de estudo: Prevalence_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos